This inventor holds 2 USPTO granted patents. Top assignee: Glaxo Group Limited. Active years: 1991-2001.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 1991-2001
Title: Kevin Ian Hammond: Innovator in Lactam Derivatives
Introduction
Kevin Ian Hammond, an accomplished inventor based in Ulverston, GB, has made significant contributions to the field of chemistry through his innovative work on lactam derivatives. With a total of 2 patents to his name, Hammond continues to push the boundaries of chemical processes that have potential applications in various industries.
Latest Patents
Hammond's latest patents focus on a novel process for the preparation of lactam derivatives. This invention outlines a detailed method for synthesizing compounds characterized by a general formula (I) that includes various substituents such as hydrogen atoms, alkyl groups, and phenyl moieties. The flexibility in the substituents allows for a wide range of possible lactam derivatives, which are essential in the synthesis of pharmaceuticals and agrochemicals.
Career Highlights
Hammond is currently employed at Glaxo Group Limited, where he applies his expertise in chemical innovation. His work emphasizes the importance of creating efficient processes in the production of valuable compounds, contributing to the advancement of the pharmaceutical industry.
Collaborations
Throughout his career, Hammond has collaborated with notable colleagues, including Ian H Coates and Alexander W Oxford. Their joint efforts have fostered a collaborative environment that drives innovation and enhances research quality within their projects.
Conclusion
Kevin Ian Hammond's contributions to the field of chemical engineering, particularly through his patents on lactam derivatives, portray him as a leading innovator. His work is not only significant in its complexity but also crucial for future advancements in various applications involving these compounds. As he continues his journey at Glaxo Group Limited, the impact of his innovations will undoubtedly resonate throughout the industry.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
